Health and racial disparity in breast cancer
doi: 10.1016/j.freeradbiomed.2010.12.028
Disclosures: Kathryn Schmidt: Nothing to Disclose, Jessica Grimm: Nothing to Disclose, Devin Copley: Nothing to Disclose, Daniel Penrice: Nothing to Disclose, Barbara Copeland: Nothing to Disclose, William Harmsen: Nothing to Disclose, Rachel Gullerud: Nothing to Disclose, Winnie Fan: Nothing to Disclose, Jordan Coffey: Nothing to Disclose, Julianne Lunde: Nothing to Disclose, Sarah Harper: Nothing to Disclose, Hugo Vargas: Sequana Medical: Consultant, Mallinckrodt: Consultant, Ocelot: Grant/Research Support, Arrowhead Phama: Grant/Research Support, Takeda: Grant/Research Support, Durect: Grant/Research Support, River2Renal: Grant/Research Support, Genfit: Grant/Research Support, Kezar Pharmaceuticals: Grant/Research Support, Blanca Lizaola-Mayo: Nothing to Disclose, Douglas Simonetto: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose 1764 PREVALENCE OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) IN THE UNITED STATES: INSIGHTS FROM NHANES 2017-2020 Ritik Mahaveer Goyal 1 Apoorva Doshi 2 Supriya Maheshwari 3 Imran Qureshi 1 Udita Gupta 3 David Kim 1 Paul Gaglio 1 , 1 Rutgers New Jersey Medical School, 2 Seth GS Medical College and KEM Hospital, Mumbai, 3 University of Alabama at Birmingham Background: Compensated Advanced Chronic Liver disease (cACLD) is described in the Baveno VI consensus which defines it as a continuum of severe fibrosis and cirrhosis as these patients are clinically inseparable
Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)
Many of these pathways overlap on key clinical issues like drug resistance, hypoxia adaptation, and CSC maintenance, indicating that targeting miRNASIRT1 interactions or their lncRNA/circRNA regulators could improve therapy or help detect the disease earlier
